Addressing the
#1 Cause of Death After a Heart Attack
We’re Reinventing the Standard of Care in Mechanical Circulatory Support
THE PROBLEM
A serious, life-threatening condition—Cardiogenic Shock
There remains a significant unmet clinical need
#1 cause of death after a heart attack
Key risk for patients with Acute Decompensated Heart Failure
Cardiogenic shock has 40%-60% mortality rate
Mechanical circulatory support (MCS) is required when the heart is unable to pump sufficient blood & oxygen to the body, resulting in end-organ failure
Significant complication risks with the current standard of care
Major bleeding
Sepsis
Infection
Vascular injury
Hemolysis
Arterial blockages leading to limb ischemia or stroke
OUR SOLUTION
Introducing Percutaneous Synchronized Cardiac Assist (PSCA)
A novel extravascular, intrapericardial device that provides ventricular augmentation without the need for vascular access or systemic anticoagulation.
Human clinical studies are currently underway to assess the preliminary safety, feasibility, and hemodynamic performance of the PSCA System in patients with cardiogenic shock. Results to-date have been presented at multiple, major cardiology conferences. Read more here.
How it works
Highly differentiated technology
This novel implant and its extravascular placement (using a simple, less invasive procedure) is designed to avoid many of the risks and complications of current, temporary MCS devices
Extravascular/extracardiac
Less invasive and avoids hemolysis, stroke
No contrast imaging
Reduces contrast-induced nephropathy
No anticoagulants
Minimizes bleeding
THE OPPORTUNITY
Platform play with multi-
billion $ global markets*
$18B
Acute Market | Cardiogenic Shock
$9B
Chronic Market | Heart Failure
Experienced Leadership Team
100+ years of combined experience successfully advancing innovation in leading MedTech companies
-
Gerardo Noriega
President/CEO
-
Albert Chin, MD
Chief Innovation Officer
-
Jim Heslin
IP Counsel
-
Susan Osborne
VP Regulatory, Clinical and Quality
-
Bezhad Behrooz
VP R&D and Operations
-
Ann Benham
Head of Marketing
World-Renowned Clinical Advisory Board
-
Daniel Burkhoff, MD, Ph.D
Director of Heart Failure,
Hemodynamics & MCS Cardiovascular
Research Foundation -
Prof. Petr Neužil, MD
Chairman, Dept of Cardiology, Na Homolce Hospital, Prague, CZ
-
Mitchell Krukoff, MD
Director, Cardiovascular Devices Unit, Duke University Medical Center
-
Kendrick Shunk, MD
Chief Interventional Cardiology UCSF/SFVA
-
Dan Meyer, MD
Chief of Cardiac Transplantation,
Baylor Scott & White Hospital Dallas -
Henry Hsia, MD
Chief of VT and Electrophysiology at UCSF, FACC,
Professor of Medicine